Halozyme Therapeutics Shares Sold by Investment Firm

GW&K Investment Management reduces stake in biopharmaceutical company

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

GW&K Investment Management LLC reduced its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 11.4% during the 3rd quarter, according to the company's recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,261,717 shares of the biopharmaceutical company's stock after selling 162,799 shares during the period.

Why it matters

Halozyme Therapeutics is a biopharmaceutical company focused on developing drug delivery technologies. The reduction in GW&K Investment Management's stake could signal a shift in investor sentiment around the company's prospects or performance.

The details

GW&K Investment Management LLC reduced its position in Halozyme Therapeutics by selling 162,799 shares during the 3rd quarter. The firm now owns 1,261,717 shares, or about 1.07% of the company's outstanding stock, valued at $92,535,000 as of the most recent SEC filing.

  • GW&K Investment Management LLC reduced its holdings in Halozyme Therapeutics during the 3rd quarter of 2026.

The players

GW&K Investment Management LLC

An investment management firm that previously held a significant stake in Halozyme Therapeutics.

Halozyme Therapeutics, Inc.

A biopharmaceutical company focused on developing drug delivery technologies.

Got photos? Submit your photos here. ›

The takeaway

The reduction in GW&K Investment Management's stake in Halozyme Therapeutics could signal a shift in investor sentiment around the company's prospects or performance, though the reasons behind the sale are not entirely clear from the information provided.